Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 148.0371
25 292.5063
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
|
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
228.3B INR |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
94.1B USD |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
72.3B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
60.5B EUR |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
26.3B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.3B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
20.3B USD |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
13.6B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR |
Loading...
|
|
| AU |
|
Sonic Healthcare Ltd
ASX:SHL
|
11B AUD |
Loading...
|
Market Distribution
| Min | -153 833.3% |
| 30th Percentile | 2.7% |
| Median | 7.3% |
| 70th Percentile | 13.2% |
| Max | 9 977% |
Other Profitability Ratios
Dr. Lal PathLabs Ltd
Glance View
Dr. Lal PathLabs Ltd. traces its origins back to 1949 when Dr. S.K. Lal, a committed professional with a vision for transforming patient care in India, laid its foundation. With a single laboratory in Delhi, the firm embarked on a journey to make diagnostic services accessible, accurate, and affordable for millions. Over the years, the company's dedication to eking out a niche in the healthcare sector was epitomized by its expansive network that bridges urban and rural India. As of today, it boasts a robust footprint with thousands of patient service centers and diagnostic facilities, enabling them to deliver high-quality pathology services across the length and breadth of the country. This network is instrumental in addressing the diagnostic needs of individuals, bringing specialized tests and healthcare packages within arm's reach of the populace, thus weaving healthcare into the fabric of everyday life. Financially, Dr. Lal PathLabs Ltd. thrives on a well-oiled operational model that deftly balances reach, scalability, and innovation. The company's revenue streams are predominantly anchored in routine and specialized pathology tests, ranging from basic blood tests to complex genetic analyses. By deploying state-of-the-art technology and adhering to high standards of quality control, the firm ensures precision, which instills trust and sustains its business growth. Additionally, strategic collaborations with hospitals, corporate health programs, and wellness initiatives further bolster its financial health. This integrative approach, coupled with a commitment to swallowing costs through operational efficiencies, allows Dr. Lal PathLabs to maintain competitive pricing strategies, thus ensuring sustainable profitability while continuing to innovate in the face of an ever-evolving healthcare landscape.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Dr. Lal PathLabs Ltd is 22.8%, which is above its 3-year median of 20.5%.
Over the last 3 years, Dr. Lal PathLabs Ltd’s Operating Margin has increased from 17.3% to 22.8%. During this period, it reached a low of 16.8% on Mar 31, 2023 and a high of 22.8% on Sep 30, 2025.